Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2007 April;142(2) > Giornale Italiano di Dermatologia e Venereologia 2007 April;142(2):137-47

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEWS  CUTANEOUS MALIGNANCY UPDATE: MELANOMA IN 2007


Giornale Italiano di Dermatologia e Venereologia 2007 April;142(2):137-47

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Melanoma chemoprevention

Freeman S. R. 1, Dellavalle R. P. 1, 2

1 Department of Dermatology University of Colorado Health Sciences Center, Aurora Colorado, USA 2 Department of Veterans Affairs Medical Center, Denver Colorado, USA


PDF  


The incidence and mortality of melanoma is steadily increasing and therapies for advanced melanoma lack efficacy. Melanoma has been proposed to originate via a series of stepwise genotypic and phenotypic changes– these stepwise changes create targets for chemoprevention. Investigation of multiple novel agents that block UV radiation, prevent activation of oncogenes and oxidative stress, exploit apoptosis, and boost the immune system suggest promising strategies for melanoma chemoprevention. A better understanding of cancer biomarkers of toxicity and drug efficacy, improved chemoprevention trial design, and heightened public awareness of the benefits of cancer prevention will facilitate efficient identification of useful chemopreventive agents. Because no agent yet emerges as a clear choice for effective melanoma chemoprevention, advising patients to avoid excessive sun exposure remains the mainstay of melanoma prevention for persons at high risk. This review summarizes recent evidence regarding potential melanoma chemopreventive agents and discusses current barriers to providing chemoprevention to patients at high risk of developing melanoma.

top of page

Publication History

Cite this article as

Corresponding author e-mail